Treats pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension). Sold as Winrevair. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Sotatercept-Csrk (sold as Winrevair), first approved Mar 26, 2024, with 2 new uses approved and 0 published complete response letters.
| Winrevair | Part D | $499M | +181% | 4,042 |
| Winrevair (2 Pack) | Part D | $285M | +3940% | 1,053 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 26, 2024 | WinrevairBLA 761363 · New molecular entity | Merck Sharp Dohme | 7 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA